Galderma’s Announcement Regarding Nemolizumab (Data Presentation at European Academy of Dermatology and Venereology)
2024-09-25 · Chugai Pharmaceutical · original chugai-pharm.co.jp ↗
TOKYO, September 25, 2024 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Galderma issued a press release today about data presentation on nemolizumab at the 2024 European Academy of Dermatology and Venereology (EADV) congress. Nemolizumab was created by Chugai, and its clinical development outside Japan is being conducted by Galderma. Please refer to the link below for details of the Galderma’s press release: EADV 2024 Late breaking news sessions: new Galderma data demonstrating nemolizumab’s long-term efficacy and safety in atopic dermatitis and durability in prurigo nodularis to be shared during three oral presentations https://www.galderma.com/news/eadv-2024-late-breaking-news-sessions-new-galderma-data-demonstrating-nemolizumabs-long-term Trademarks used or mentioned in this release are protected by laws.
The release as fetched from its publisher. chugai-pharm.co.jp ↗